Dedicated to finding a
cure for brain cancer
Emerging Leader Grant Award
The Ben & Catherine Ivy Foundation Emerging Leader Award provides grant support to early-to-mid-career investigators conducting high-impact, high-reward translational research for glioblastoma. This award is intended to support ambitious pilot projects designed to identify drug strategies appropriate for early-phase pharmacodynamic- and pharmacokinetic-driven clinical trials in partnership with the Ivy Brain Tumor Center.
Translational Adult Glioma Award
The Ben & Catherine Ivy Foundation Emerging Adult Glioma Award provides grant support to investigators conducting high-impact, high-reward translational research for glioblastoma. This award is intended to support projects designed to contribute to identifying therapies that will impact the survival of patients with brain cancer.
Introducing the Largest Phase 0 Clinical Trials Program in the World
The Ivy Brain Tumor Center is a nonprofit translational research program that offers state-of-the-art clinical trials for patients with aggressive brain tumors.
PHASE 0 TRIALS
Ivy Phase 0 clinical trials allow patients to receive individualized treatment in a fraction of the time and costs associated with traditional drug research and development. This approach addresses the two most common reasons most drugs fail in brain tumor patients:
- Most new drugs are incapable of reaching the brain.
- Laboratory animal studies of new drugs paint an incomplete picture of how the drugs will perform in humans.
Nick : Ivy Center Patient Survivor
The day after his graduation from San Diego State University, Nick was diagnosed with a recurrence of his malignant meningioma. Nick knew he wasn’t going to have a lot of options, but the Ivy Center had just opened a Phase 0 clinical trial for this exact indication.
Sanjiv Sam Gambhir M.D., Ph.D
Ivy Foundation Honored
The Mayo Clinic and Ivy Foundation
A Message from Catherine Ivy
The Ivy Foundation has the long-term, ultimate goal to cure brain cancer. To that end, we fund cutting-edge research that will improve diagnostics and treatment options for patients with brain cancer. Since 2005, we’ve committed more than $100 million to brain tumor research, with the expectation that this will lead to an eventual cure. We are dedicated to this effort because funding leads to answers, and answers lead to hope.